Overview

Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection

Status:
Terminated
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Treatment of acute primary HIV infection may improve long-term outcome. However, optimal treatment is still debated. The ANRS 112-INTERPRIM trial evaluates three different therapeutical strategies, combining permanent or intermittent HAART and a cytokine, interferon alpha, in order to determine which combination allows the best control of HIV viremia after 24 weeks of antiretroviral treatment interruption
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborator:
Hoffmann-La Roche
Treatments:
Anti-Retroviral Agents
Interferon-alpha
Interferons